Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer

Inoue, Masayoshi; Maeda, Hitoshi; Takeuchi, Yukiyasu; Fukuhara, Kenjiro; Shintani, Yasushi; Funakoshi, Yasunobu; Funaki, Soichiro; Nojiri, Takashi; Kusu, Takashi; Kusumoto, Hidenori; Kimura, Tōru; Okumura, Meinoshin

doi:10.1007/s00595-017-1594-7

Cited by 5 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CD-DST is a culture-based anticancer drug susceptibility test that uses fresh tumor tissues obtained from various excised solid tumors that have a high probability of growth in in vitro environments. The usefulness of CD-DST has been demonstrated in lung cancer[15-17], gastric cancer[18], colorectal cancer[19,20], and MPM studies[21]. In our case, the cultured cancer cells were resistant to PEM but highly sensitive to GEM.…”

Section: Discussionmentioning

confidence: 61%

In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report

Taguchi

Tatenuma

Okada

et al. 2019

WJCC

View full text Add to dashboard Cite

BACKGROUNDWe report the first case, to the best of our knowledge, of massive ascites due to recurrent malignant pleural mesothelioma that was controlled using KM-cell-free and concentrated ascites reinfusion therapy (KM-CART). The tumor cells derived via KM-CART were utilized secondarily in an in vitro cell growth assay using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) to investigate anticancer drug susceptibility.CASE SUMMARYA 56-year-old man presented with recurrent malignant mesothelioma with massive ascites; more than 4000 mL of ascitic fluid was removed, filtered, and concentrated using KM-CART, and the cell-free ascitic fluid was reinfused into the patient to improve quality of life. Cancer cells isolated secondarily in an in vitro proliferation assay using CD-DST exhibited low sensitivity to pemetrexed and high sensitivity to gemcitabine. Treatment with gemcitabine maintained stable disease for 4 mo.CONCLUSIONThe combination of KM-CART and CD-DST may be a promising treatment option for malignant ascites associated with malignant mesothelioma.

show abstract

Section: Discussionmentioning

confidence: 61%

In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report

Taguchi

Tatenuma

Okada

et al. 2019

WJCC

View full text Add to dashboard Cite

show abstract

“…To ensure the reliability of CSRA, technical performances must be linked to clinical benefits. Among 27 clinical studies listed in our meta-analysis (Table 3 ), only two of them failed to find significant benefits for the patients 88 , 93 . Most of these studies were retrospective evaluations and allowed to correlate chemo-responses to clinical outcomes.…”

Section: Overview Of Csra Clinical Performancesmentioning

confidence: 96%

Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept

et al. 2021

View full text Add to dashboard Cite

As complex and heterogeneous diseases, cancers require a more tailored therapeutic management than most pathologies. Recent advances in anticancer drug development, including the immuno-oncology revolution, have been too often plagued by unsatisfying patient response rates and survivals. In reaction to this, cancer care has fully transitioned to the “personalized medicine” concept. Numerous tools are now available tools to better adapt treatments to the profile of each patient. They encompass a large array of diagnostic assays, based on biomarkers relevant to targetable molecular pathways. As a subfamily of such so-called companion diagnostics, chemosensitivity and resistance assays represent an attractive, yet insufficiently understood, approach to individualize treatments. They rely on the assessment of a composite biomarker, the ex vivo functional response of cancer cells to drugs, to predict a patient's outcome. Systemic treatments, such as chemotherapies, as well as targeted treatments, whose efficacy cannot be fully predicted yet by other diagnostic tests, may be assessed through these means. The results can provide helpful information to assist clinicians in their decision-making process. We explore here the most advanced functional assays across oncology indications, with an emphasis on tests already displaying a convincing clinical demonstration. We then recapitulate the main technical obstacles faced by researchers and clinicians to produce more accurate, and thus more predictive, models and the recent advances that have been developed to circumvent them. Finally, we summarize the regulatory and quality frameworks surrounding functional assays to ensure their safe and performant clinical implementation. Functional assays are valuable in vitro diagnostic tools that already stand beyond the “proof-of-concept” stage. Clinical studies show they have a major role to play by themselves but also in conjunction with molecular diagnostics. They now need a final lift to fully integrate the common armament used against cancers, and thus make their way into the clinical routine.

show abstract

“…CD-DST byl využit k predikci rezistence pacientů s hepatocelulárním karcinomem k standardně podávané léčbě a v související klinické studii umožnil poměrně spolehlivě stanovit, který z pacientů bude z adjuvantní chemoterapie skutečně profitovat [65,66]. Jen v roce 2017 bylo publikováno hned několik prací, které se zabývaly aplikací CD-DST u dalších malignit, jako je karcinom dutiny ústní, plic nebo nádory trávicího traktu [65,67,68]. …”

Section: D In Vitro Modelyunclassified

New Approaches for Chemosensitivity Testing in Malignant Diseases

Sommerová¹,

Michalová²,

Hrstka³

2018

Klin Onkol

View full text Add to dashboard Cite

Východiska: Vzhledem k nezastupitelné úloze chemoterapie při léčbě nádorových onemocnění se onkologický výzkum zaměřil na zvýšení účinnosti jednotlivých léčiv a maximální zmírnění, ne-li kompletní potlačení nežádoucích účinků. Vhodná léčba je primárně volena podle základních klinicko-patologických dia gnostických kritérií, jako je velikost nádoru, stupeň diferenciace a přítom-nost či absence standardních markerů. Situaci však komplikuje variabilita mezi jednotlivými pacienty spolu se značnou heterogenitou vlastního nádoru. Detailní charakterizace intratumorální heterogenity a získání spolehlivějších ukazatelů účinnosti léčiv by tak mělo vést k posílení personalizované terapie. Vývoj a výběr spolehlivých modelů tudíž představuje důležitou otázku ve vý-zkumu zaměřeném na predikci citlivosti nádorových buněk k léčbě. Cíl: Práce shrnuje poznatky o testovacích systémech zaměřených na stanovení citlivosti či rezistence nádorových buněk k chemoterapii a jejich zavádění do onkologické praxe od prvních dnes již historických pokusů až po současnost se snahou posoudit jejich uplatnění ve stávající klinické praxi či blízké budoucnosti. Značný důraz je kladen na porovnání 2D a 3D in vitro buněčných modelů, neboť jejich význam a popularita konstantně narůstá. Pozornost je též věnovaná systémům in vivo, které v poslední době zaznamenaly nemalý progres a jsou v rámci klinických studií testovány k predikci odpovědi na podávanou terapii. Závěr: Práce uvádí stručný přehled testů chemosenzitivity a hodnotí význam jednotlivých testů vzhledem k jejich zapojení do rozhodovacího procesu a stratifikace pacientů s cílem predikovat klinickou odpověď konkrétních pacientů a přispět tak k rozvoji cílené personalizované terapie. Klíčová slovatechniky tkáňových kultur -individualizovaná medicína -screening léčiv -bio logické modely -nádorové buněčné linie -karcinom -cytotoxické testy SummaryBackground: Due to the irreplaceable role of chemotherapy in cancer treatment, research has focused on improving the efficacies of individual drugs and minimizing, or completely suppressing, their negative side effects. Based on long-term experience and the results of clinical trials, the selection of appropriate treatment is currently based on classical clinical dia gnostic criteria, such as tumor size, grade, and the presence or absence of standard markers. However, complications arise due to variability between patients and tumor heterogeneity. Characterization of intratumoral heterogeneity and acquisition of more reliable drug performance indicators should improve personalized therapy. Development and selection of suitable models are therefore important issues in cancer research focused on predicting sensitivity to therapy. Aim: This work provides an overview of various chemosensitivity tests that have been previously employed and those that are currently used. Great emphasis is placed on comparing 2D and 3D cell culture models, since their importance and popularity are increasing. Particular attention is paid to in vivo systems, which have significantl...

show abstract

Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer

Abstract: CD-DST can be used to evaluate chemosensitivity after lung cancer surgery; however, its clinical efficacy for assessing individualized treatment remains uncertain.

Cited by 5 publications

References 19 publications

In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report

In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report

Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept

New Approaches for Chemosensitivity Testing in Malignant Diseases

Contact Info

Product

Resources

About